Europe approves Tasigna for first-line CML
This article was originally published in Scrip
Novartis completed the full set of major market approvals just before the Christmas break when the European Commission gave the green light to the Swiss major's Tasigna (nilotinib) for treatment of patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in chronic phase. The US Food & Drug Administration, Japan's Ministry of Health, Labour and Welfare and Swissmedic had previously approved Tasigna in the first-line indication.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.